Quotes delayed at least 20 minutes.
Information provided by TurboFeed.

XOMA is a leader in the discovery, development and manufacture of therapeutic antibodies. XOMA’s exceptionally broad technology platform, leading scientific expertise, and fully integrated product development infrastructure, extends from antibody discovery to regulatory approval. A proven development partner and technology licensor, XOMA receives royalties from Genentech for RAPTIVA® (efalizumab) and LUCENTIS® (ranibizumab injection). Our pipeline includes an expanding number of proprietary products and collaborative programs at various stages of clinical and preclinical development.

Recent News

May 5, 2008
XOMA to Announce First Quarter 2008 Financial Results and Host Conference Call on Monday, May 12

Apr 1, 2008
XOMA Announces New Audit Committee Member

more »

Events

May 12, 2008
XOMA Ltd. First Quarter 2008 Financial Results Conference Call

more »